B细胞受体信号活动识别了地幔细胞淋巴瘤患有更高进展风险的患者
Simona Gambino1, Francesca Maria Quaglia2, Marilisa Galasso1
1Department of Engineering for Innovation Medicine, Section of Biomedicine, University of Verona, Verona, Italy.
Scientific reports
|March 20, 2024
概括
在地幔细胞淋巴瘤 (MCL) 中识别B细胞受体 (BCR) 信号模式可以预测患者的治疗结果和对布鲁顿氨酸激酶抑制剂 (BTKi) 的耐药性. 这些发现为这种无法治愈的B细胞恶性瘤提供了新的预后标志物.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 薄膜细胞淋巴瘤 (MCL) 是一种具有显著临床变异性的不可治愈的B细胞恶性瘤.
- 识别高风险患者和治疗耐药性的预后标志物对于有效的MCL管理至关重要.
研究的目的:
- 在初级MCL样本中调查B细胞受体 (BCR) 信号异质性.
- 为了将BCR信号模式与临床结果和对布鲁顿氨酸激酶抑制剂 (BTKi) 的反应相关联.
主要方法:
- 在30个初级MCL样本中使用特异流细胞计分析BCR信号蛋白 (SYK,LCK,BTK,PLCγ2,p38,AKT,NF-κB p65,STAT5).
- 使用抗IgM调制来评估差异性的BCR信号响应,识别患者群.
- 进行了时间到事件分析,将信号数据与无进展生存期 (PFS) 和总生存期 (OS) 相关联.
主要成果:
- 确定了两个不同的BCR信号响应集群,较高的响应与较短的PFS和OS相关.
- 构成性AKT活动预测对BTKi ibrutinib的反应较差.
- 高MCL国际预测指数 (MIPI) 和高STAT5反应预测了更短的PFS和OS,而高MIPI和SYK反应预测了更短的OS.
结论:
- BCR信号特性与MCL的不良临床结果有关.
- 特定的BCR信号模式可以预测对ibrutinib的耐药性,强调预后和预测意义.
- 了解BCR信号异质性可以提高对MCL临床行为和治疗策略的了解.
相关概念视频
B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Cells of the Adaptive Immune Response
985
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
985
T Cell Activation and Clonal Selection
726
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
726
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K


